MM Hoeper, E Mayer, G Simonneau, LJ … - Circulation, 2006 - Am Heart Assoc Chronic thromboembolic pulmonary hypertension (CTEPH) has emerged as one of the
leading causes of severe pulmonary hypertension. The disease is notoriously
underdiagnosed, and the true prevalence is still unclear. CTEPH is ... Cited by 124 - Related articles - All 6 versions
N Benedict, A Seybert, MA Mathier - Clinical therapeutics, 2007 - Elsevier Results: In two 12-week, randomized, open-label trials in patients with moderate
to severe PAH (N = 81 and N = 111), exercise capacity, measured on the 6-minute
walk test (6-MWT), was significantly improved with intravenous epoprostenol ... Cited by 25 - Related articles - All 6 versions
SR Johnson, S Mehta, JT Granton - European Respiratory Journal, 2006 - ersj.org.uk 1 Division of Rheumatology, and 3 Pulmonary Hypertension Centre, University
Health Network, University of Toronto, Toronto, and 2 Southwest Ontario
Pulmonary Hypertension Clinic and Centre For Critical Illness Research, ... Cited by 22 - Related articles - BL Direct - All 7 versions
- ►cchd.com.cn [PDF] MGJ Duffels, PM Engelfriet, RMF Berger, RLE … - International journal of cardiology, 2007 - Elsevier The prevalence of PAH among all 5970 registered adult patients with congenital
heart disease was 4.2%. Of 1824 patients with a septal defect in the registry,
112 patients (6.1%) had PAH. Median age of these patients was 38 years ... Cited by 24 - Related articles - All 9 versions
- ►chestpubs.org RP Baughman, BK Sparkman, EE Lower - Chest, 2007 - chestjournal.chestpubs.org Results: One hundred three of 142 patients had extrapulmonary manifestations, 10
patients had left ventricular dysfunction, and 14 patients had documented
pulmonary hypertension. Seventy-three patients (51%) completed a 6MWD < 400 ... Cited by 19 - Related articles - BL Direct - All 6 versions
RJ Barst - Vascular Health and Risk Management, 2007 - pubmedcentral.nih.gov Pulmonary arterial hypertension (PAH) is a rare fatal disease. Current
disease-specific therapeutic interventions in PAH target 1 of 3 established
pathways in disease pathobiology: prostacyclin, nitric oxide, and ... Cited by 18 - Related articles - BL Direct - All 9 versions
RP Baughman, PJ Engel, CA Meyer, AB … - Sarcoidosis Vasc Diffuse Lung Dis, 2006 - ildcare.nl Abstract. Background: Pulmonary hypertension has been notreported in some
patients with sarcoidosis. Methods: We retrospectively studied 53 sarcoidosis
patients with persistent dyspnea despite systemic ther- apy for their ... Cited by 18 - Related articles - View as HTML - All 4 versions
- ►scielo.br [PDF] MS Lapa, EVM Ferreira, C Jardim, BCS … - Revista da Associação Médica Brasileira, 2006 - SciELO Brasil *Correspondência: Rogerio Souza R. Afonso de Freitas, 451, ap. 112 São Paulo,
SP Cep: 04006-052 rogerio.souza@incor.usp.br ... RESUMO O BJETIVOS . Descrever
as características clínicas dos pacientes com hipertensão pulmonar de ... Cited by 18 - Related articles - View as HTML - All 2 versions
- ►mayoclinicproceedings.com JH Ryu, MJ Krowka, KL Swanson, PA … - Mayo Clinic Proceedings, 2007 - mayoclinicproceedings.com Pulmonary hypertension (PH) in patients with interstitial lung diseases (ILDs)
is not well recognized and can occur in the absence of advanced pulmonary
dysfunction or hypoxemia. To address this topic, we identified relevant ... Cited by 16 - Related articles - BL Direct - All 10 versions
A Raiesdana, J Loscalzo - Annals of Medicine, 2006 - informahealthcare.com Pulmonary arterial hypertension is a disease of the small pulmonary arteries
characterized by vascular narrowing and increased pulmonary vascular resistance,
which eventually leads to right ventricular failure. Vasoconstriction, ... Cited by 15 - Related articles - BL Direct - All 8 versions
